Clinical trial
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating…
NCT00066326 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00066326 |
|---|---|
| Title | Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesylate, tanespimycin |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Aug 7, 2003 |
| Last update posted | Apr 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: